INCY Incyte

Q1 2025 10-Q

Filed: Apr 29, 2025Period ending Mar 31, 2025

Industrials

Services-Commercial Physical & Biological ResearchSEC EDGAR

Incyte (INCY) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Apr 29, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Management Discussion & Analysis

• Revenues $1,052.9M, up 19.5% YoY from $880.9M; JAKAFI $709.4M (+24.1%), OPZELURA $118.7M (+38.6%)
• Net income $158.2M, down 6.6% YoY from $169.5M; basic EPS $0.82 vs $0.76 YoY; operating margin affected by cost increases

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.1B

▲ +19.5% YoY

Net Income

$158M

▼ -6.7% YoY

Operating Margin

19.5%

▲ +905bp YoY

Net Margin

15.0%

▼ -422bp YoY

EPS (Diluted)

$0.80

▲ +6.7% YoY

Operating Cash Flow

$266M

▲ +21.6% YoY

Source: XBRL data from Incyte Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Incyte Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Incyte

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.